Hyperinsulinemic Normoglycemia during Cardiac Surgery Reduces a Composite of 30-day Mortality and Serious In-hospital Complications: A Randomized Clinical Trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 1300217 Publication Model: Print Cited Medium: Internet ISSN: 1528-1175 (Electronic) Linking ISSN: 00033022 NLM ISO Abbreviation: Anesthesiology
    • Publication Information:
      Publication: Philadelphia Pa : Lippincott Williams & Wilkins
      Original Publication: Philadelphia : American Society of Anesthesiologists
    • Subject Terms:
      Blood Glucose/*metabolism ; Cardiac Surgical Procedures/*mortality ; Hospitalization/*trends ; Hyperinsulinism/*mortality ; Intraoperative Care/*mortality ; Postoperative Complications/*mortality; Aged ; Aged, 80 and over ; Cardiac Surgical Procedures/adverse effects ; Cardiac Surgical Procedures/trends ; Female ; Glycemic Index/physiology ; Humans ; Hyperinsulinism/blood ; Insulin/blood ; Intraoperative Care/methods ; Intraoperative Care/trends ; Male ; Middle Aged ; Mortality/trends ; Postoperative Complications/blood
    • Abstract:
      Background: Hyperinsulinemic normoglycemia augments myocardial glucose uptake and utilization. We tested the hypothesis that hyperinsulinemic normoglycemia reduces 30-day mortality and morbidity after cardiac surgery.
      Methods: This dual-center, parallel-group, superiority trial randomized cardiac surgical patients between August 2007 and March 2015 at the Cleveland Clinic, Cleveland, Ohio, and Royal Victoria Hospital, Montreal, Canada, to intraoperative glycemic management with (1) hyperinsulinemic normoglycemia, a fixed high-dose insulin and concomitant variable glucose infusion titrated to glucose concentrations of 80 to 110 mg · dl; or (2) standard glycemic management, low-dose insulin infusion targeting glucose greater than 150 mg · dl. The primary outcome was a composite of 30-day mortality, mechanical circulatory support, infection, renal or neurologic morbidity. Interim analyses were planned at each 12.5% enrollment of a maximum 2,790 patients.
      Results: At the third interim analysis (n = 1,439; hyperinsulinemic normoglycemia, 709, standard glycemic management, 730; 52% of planned maximum), the efficacy boundary was crossed and study stopped per protocol. Time-weighted average glucose concentration (means ± SDs) with hyperinsulinemic normoglycemia was 108 ± 20 versus 150 ± 33 mg · dl with standard glycemic management, P < 0.001. At least one component of the composite outcome occurred in 49 (6.9%) patients receiving hyperinsulinemic normoglycemia versus 82 (11.2%) receiving standard glucose management (P < efficacy boundary 0.0085); estimated relative risk (95% interim-adjusted CI) 0.62 (0.39 to 0.97), P = 0.0043. There was a treatment-by-site interaction (P = 0.063); relative risk for the composite outcome was 0.49 (0.26 to 0.91, P = 0.0007, n = 921) at Royal Victoria Hospital, but 0.96 (0.41 to 2.24, P = 0.89, n = 518) at the Cleveland Clinic. Severe hypoglycemia (less than 40 mg · dl) occurred in 6 (0.9%) patients.
      Conclusions: Intraoperative hyperinsulinemic normoglycemia reduced mortality and morbidity after cardiac surgery. Providing exogenous glucose while targeting normoglycemia may be preferable to simply normalizing glucose concentrations.
    • References:
      J Thorac Cardiovasc Surg. 2005 Oct;130(4):1144. (PMID: 16214532)
      Acta Anaesthesiol Scand. 2006 Sep;50(8):954-61. (PMID: 16923090)
      Anesthesiology. 2015 Jun;122(6):1214-23. (PMID: 25992877)
      ARYA Atheroscler. 2010 Summer;6(2):62-8. (PMID: 22577416)
      Can J Cardiol. 2010 Jun-Jul;26(6):178-84. (PMID: 20548978)
      J Clin Endocrinol Metab. 2011 May;96(5):1469-77. (PMID: 21346060)
      Am J Physiol Endocrinol Metab. 2007 May;292(5):E1288-94. (PMID: 17213470)
      J Thorac Cardiovasc Surg. 1997 Feb;113(2):354-60; discussion 360-2. (PMID: 9040630)
      J Clin Endocrinol Metab. 2010 Sep;95(9):4338-44. (PMID: 20631016)
      Cardiovasc Res. 1997 Feb;33(2):243-57. (PMID: 9074687)
      J Am Coll Cardiol. 2005 Jul 5;46(1):42-8. (PMID: 15992633)
      Stat Med. 2009 Nov 10;28(25):3083-107. (PMID: 19757444)
      J Cardiovasc Pharmacol. 1994;24 Suppl 3:S61-9. (PMID: 7700069)
      Metab Syndr Relat Disord. 2017 Jun;15(5):252-257. (PMID: 28394194)
      N Engl J Med. 2008 Jan 10;358(2):125-39. (PMID: 18184958)
      J Anesth. 2017 Apr;31(2):185-192. (PMID: 28004200)
      Ann Intern Med. 2007 Feb 20;146(4):233-43. (PMID: 17310047)
      Lancet. 2000 Mar 4;355(9206):773-8. (PMID: 10711923)
      Circ Res. 2001 Dec 7;89(12):1191-8. (PMID: 11739285)
      N Engl J Med. 2001 Nov 8;345(19):1359-67. (PMID: 11794168)
      Intensive Care Med. 2009 Oct;35(10):1738-48. (PMID: 19636533)
      Scand Cardiovasc J. 2000 Jun;34(3):321-30. (PMID: 10935781)
      N Engl J Med. 2006 Feb 2;354(5):449-61. (PMID: 16452557)
      Anesthesiology. 2015 Aug;123(2):272-87. (PMID: 26200180)
      Circ Res. 1991 Feb;68(2):466-81. (PMID: 1991351)
      Ann Thorac Surg. 1999 Feb;67(2):352-60; discussion 360-2. (PMID: 10197653)
      Stat Med. 1990 Dec;9(12):1439-45. (PMID: 2281231)
      Circulation. 2011 Jan 18;123(2):170-7. (PMID: 21200004)
      Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H939-H945. (PMID: 18660443)
      Physiol Rev. 2005 Jul;85(3):1093-129. (PMID: 15987803)
      Braz J Med Biol Res. 2007 Aug;40(8):1037-44. (PMID: 17665039)
      PLoS One. 2014 Jun 18;9(6):e99661. (PMID: 24941010)
      Br J Surg. 2017 Jan;104(2):e95-e105. (PMID: 27901264)
      Stroke. 2001 Oct;32(10):2426-32. (PMID: 11588337)
      N Engl J Med. 2009 Mar 26;360(13):1283-97. (PMID: 19318384)
      N Engl J Med. 2012 Sep 20;367(12):1108-18. (PMID: 22992074)
      Eur J Cardiothorac Surg. 2006 Apr;29(4):479-85. (PMID: 16481185)
      J Thorac Cardiovasc Surg. 2000 Jun;119(6):1176-84. (PMID: 10838535)
      Lancet. 2009 Feb 14;373(9663):547-56. (PMID: 19176240)
      Anesthesiology. 2005 Oct;103(4):687-94. (PMID: 16192760)
      J Am Coll Cardiol. 2002 Feb 20;39(4):718-25. (PMID: 11849874)
      Anesth Analg. 2004 Aug;99(2):319-24, table of contents. (PMID: 15271698)
      Circulation. 2004 Mar 30;109(12):1497-502. (PMID: 15006999)
      Crit Care Med. 2005 Jul;33(7):1624-33. (PMID: 16003073)
      Am J Cardiol. 1997 Aug 4;80(3A):90A-93A. (PMID: 9293960)
      Endocr Pract. 2004 Mar-Apr;10 Suppl 2:21-33. (PMID: 15251637)
      J Clin Endocrinol Metab. 2017 Sep 1;102(9):3400-3405. (PMID: 28666346)
      J Cardiothorac Vasc Anesth. 2011 Dec;25(6):1086-91. (PMID: 21757376)
      Eur J Anaesthesiol. 2015 Aug;32(8):555-62. (PMID: 25760680)
      J Cardiovasc Surg (Torino). 2005 Dec;46(6):569-76. (PMID: 16424845)
      Anesth Analg. 2011 Jun;112(6):1461-71. (PMID: 21543784)
      Ann Thorac Surg. 2007 Dec;84(6):1920-7; discussion 1920-7. (PMID: 18036907)
    • Grant Information:
      K23 HL093065 United States HL NHLBI NIH HHS
    • Accession Number:
      0 (Blood Glucose)
      0 (Insulin)
    • Publication Date:
      Date Created: 20180315 Date Completed: 20190820 Latest Revision: 20200306
    • Publication Date:
      20240829
    • Accession Number:
      PMC6509049
    • Accession Number:
      10.1097/ALN.0000000000002156
    • Accession Number:
      29537981